Leccinum vulpinum Watling induces DNA damage, decreases cell proliferation and induces apoptosis on the human MCF-7 breast cancer cell line by Reis, Filipa S. et al.
1 
 
Leccinum vulpinum Watling induces DNA damage, decreases cell 
proliferation and induces apoptosis on the human MCF-7 breast 
cancer cell line 
Filipa S. Reisa,b,c,d, Diana Sousaa,b,e, Lillian Barrosc, Anabela Martinsc, Patricia 
Moralesd, Isabel C.F.R. Ferreirac*, M. Helena Vasconcelosa,b,e,* 
 
ai3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Rua 
Alfredo Allen, 208, 4200-135 Porto, Portugal. 
bCancer Drug Resistance Group, IPATIMUP – Institute of Molecular Pathology and 
Immunology of the University of Porto, Rua Júlio Amaral de Carvalho, 45, 4200-135 
Porto, Portugal. 
cMountain Research Centre (CIMO), ESA, Polytechnic Institute of Bragança, Campus 
de Santa Apolónia, 1172, 5301-855 Bragança, Portugal. 
dDpto. Nutrición y Bromatología II, Facultad de Farmacia, Universidad Complutense 
de Madrid (UCM), Pza Ramón y Cajal, s/n, E-28040 Madrid, Spain. 
eLaboratory of Microbiology, Department of Biological Sciences, Faculty of Pharmacy 
of the University of Porto, Rua de Jorge Viterbo Ferreira n.º 228, 4050-313 Porto, 
Portugal. 
 
*Corresponding authors: Isabel C.F.R. Ferreira; e-mail: iferreira@ipb.pt; telephone 
+351-273-303219; fax +351-273-325405. M. Helena Vasconcelos; e-mail: 
hvasconcelos@ipatimup.pt; telephone +351-225570700; fax +351-225570799. 
 
 
2 
 
ABSTRACT 
The current work aimed to study the antitumour activity of a phenolic extract of the 
edible mushroom Leccinum vulpinum Watling, rich essentially in hydroxybenzoic acids. 
In a first approach, the mushroom extract was tested against cancer cell growth by using 
four human tumour cell lines. Given the positive results obtained in these initial 
screening experiments and the evidence of some studies for an inverse relationship 
between mushroom consumption and breast cancer risk, a detailed study of the 
bioactivity of the extract was carried out on MCF-7 cells. Once the selected cell line to 
precede the work was the breast adenocarcinoma cell line, the human breast non-
malignant cell line MCF-10A was used as control.  
Overall, the extract decreased cellular proliferation and induced apoptosis. Furthermore, 
the results also suggest that the extract causes cellular DNA damage. Data obtained 
highlight the potential of mushrooms as a source of biologically active compounds, 
particularly with antitumour activity. 
 
 
Keywords: Mushrooms, phenolic extract, bioactive compounds, antitumour potential, 
apoptosis, DNA damage. 
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1. Introduction 
It is recognized worldwide that mushrooms are an excellent food both from a nutritional 
and bioactive point of view (Cheung, 2010; Roupas et al., 2012; Wasser, 2011). Indeed, 
according to the literature, in addition to their nutritional value, mushrooms have also 
been recognized for their therapeutic value (Öztürk et al., 2015). 
Among these health benefits, the antitumor potential of different mushroom species 
and/or their components is well recognized by the scientific community (Ferreira et al., 
2010). Actually, there is some evidence (from case-control studies in humans subjected 
to controlled diets) of an inverse relationship between the consumption of mushrooms 
and breast cancer risk (Hong et al., 2008; Roupas et al., 2012; Shin et al., 2010; Zhang 
et al., 2009). Moreover, there are some studies attesting the beneficial effects of some 
mushroom extracts in cancer patients. An Agaricus blazei extract has been reported to 
have beneficial effects in gynecological cancer patients undergoing chemotherapy, 
maintaining their immune activities and improving their quality of life (Ahn et al., 
2004). Furthermore, the efficacy of PSK (Polysaccharide-K, obtained from Trametes 
versicolor) as an adjuvant immunotherapy agent after surgery has been described, in 
patients with colorectal cancer by increasing the patients survival and reducing the 
recurrence risk (Ito et al., 2004; Mitomi et al., 1992; Ohwada et al., 2004; Torisu et al., 
1990), as well as in patients with gastric cancer (Nakazato et al., 1994; Tsujitani et al., 
1992). In addition, dietary supplementation with an extract from Agaricus sylvaticus 
showed to be beneficial in postsurgical patients with colorectal cancer (Fortes et al., 
2009). 
The phenolic compounds are amongst the compounds with higher bioactivity (Öztürk et 
al., 2015). Indeed, the phenolic compounds, present in both wild and cultivated 
mushrooms, have been recognized as bioactive compounds which may be extracted for 
the purpose of being used as functional constituents (Cheung, 2010; Palacios et al., 
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2011; Patel and Goyal, 2012; Reis et al., 2012; Vaz et al., 2012a). Likewise, mushrooms 
might be used directly in diet, promoting health benefits and taking advantage of the 
additive and synergistic effects of their bioactive compounds (Ferreira et al., 2009).  
There are very few studies on the Leccinum vulpinum Watling mushroom species. To 
our knowledge, such studies have only outlined its morphological description (Ellis and 
Ellis, 1990), as well as some of its ecological (Iwański and Rudawska, 2007; Saxén and 
Ilus, 2008; Vaaramaa et al., 2009) and enzymatic characteristics (Chen et al., 2001 and 
2003).  
Taking into account the facts aforementioned regarding the potential of mushrooms and 
their components, and since there are no studies on L. vulpinum bioactivity, in the 
present work the antitumour potential of a phenolic extract obtained from this species 
was evaluated. The extract was initially chemically characterized by chromatographic 
techniques so as to measure their phenolic acids content. Afterwards, the extract was 
tested against a panel of four human tumour cell lines, in order to perform a first 
assessment of its effect on the growth of human tumour cell lines. Moreover, some 
functional assays were performed in order to further evaluate the effects of the phenolic 
extract on the MCF-7 cells (i.e., cell proliferation, cell cycle profile and apoptosis). 
Additionally, the effects of the extract as an inducer of DNA damage were also 
evaluated, given that DNA damage is a mechanism of action of several cytotoxic drugs, 
which may lead to cell cycle arrest (inhibiting proliferation) and apoptosis. 
 
2. Material and methods 
2.1. Mushroom species and samples preparation 
Leccinum vulpinum Watling wild samples were collected in Bragança (Northeast of 
Portugal) in the autumn of 2012. Authentications were undertaken at the Polytechnic 
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Institute of Bragança and voucher specimens were deposited at the herbarium of the 
School of Agriculture of the Polytechnic Institute of Bragança, Portugal. 
All samples were lyophilised (FreeZone 4.5 model 7750031, Labconco, Kansas City, 
MO, USA), reduced to a fine dried powder (20 mesh), mixed and stored in a desiccator, 
protected from light.  
 
2.2. Extraction procedure and chromatographic characterization of the extract 
The extraction procedure and chromatographic characterization were performed 
according to the procedure described by other authors (Reis et al., 2012). Briefly, 
approximately 1.5 g of lyophilized sample was extracted with methanol:water (80:20, 
v/v; 30 mL) at -20°C. The analysis of phenolic compounds contained in the sample was 
performed by ultra fast liquid chromatography (UFLC, Shimadzu 20A series; UFLC, 
Shimadzu Coperation, Kyoto, Japan) and the detection was carried out in a photodiode 
array detector (PDA), using 280 nm as the preferred wavelength. The phenolic 
compounds present in the studied extract were characterised according to their UV and 
retention times compared with commercial standards. The quantitative analysis of the 
compounds, was based on the calibration curve obtained by the injecting of known 
concentrations of each standard compound: cinnamic acid, gallic acid, p-
hydroxybenzoic acid and protocatechuic acid. The results were expressed in µg per g of 
extract. 
For the biological assays, the residue extracts were re-dissolved in distillated water (8 
mg/mL). 
 
2.3. Screening for the cell growth inhibitory activity in human tumour cell lines and 
cytotoxicity evaluation 
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The screening for tumour cell growth inhibitory activity was carried out using the 
sulforhodamine B (SRB) assay, a procedure adopted by the NCI’s in vitro anticancer 
drug screening (Neves et al., 2011; Vichai and Kirtikara, 2006). This colorimetric assay 
estimates the cell number indirectly, by staining cellular protein with SRB. Four human 
tumour cell lines were used: MCF-7 (breast adenocarcinoma), NCI-H460 (non-small 
cell lung cancer), HCT-15 (colorectal adenocarcinoma) and AGS (gastric 
adenocarcinoma). The choice of the cell lines was performed in accordance with the 
mortality rate of the cancer type. As reported by the Cancer Research UK (data from 
2012; Cancer Research UK, 2014), lung cancer is definitely the most common cause of 
cancer deaths, in both men and women. It accounts for just about 23% of all male 
deaths and 21% for female deaths.  The second leading cause of cancer death in women, 
is the breast cancer (15% of all female cancer deaths), therefore the importance of its 
study. HCT-15 cell line was chosen since the bowel cancer is the 3th cause of death in 
both men and women, responsible for 10% of cancer deaths. Although stomach cancer 
mortality is strongly related to age, this type of cancer is the 3rd most common cause of 
cancer death worldwide (considering both genders) and the 4th most common cause of 
cancer death in Europe. Therefore, this cell line was also selected to be included in the 
studied panel of human tumour cells. Cells were routinely maintained as adherent cell 
cultures in RPMI-1640 medium containing 5% heat-inactivated FBS, in a humidified air 
incubator containing 5% CO2. Cells were plated in 96-well plates at an appropriate 
density (5.0 × 103 cells/well for MCF-7 and NCI-H460, 1.0 × 104 cells/well for HCT-15 
and 7.5 × 103 cells/well for AGS) and allowed to adhere for 24 h. Since different cells 
have different growth rates, the optimal cell density to be plated for each cell line was 
previously optimised, based on NCI’s in vitro anticancer drug screening with some 
alterations, in order to prevent the cells from reaching confluence during the duration of 
the assay (which per se would cause cell cycle arrest and apoptosis) (Azevedo et al., 
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2013; Vaz et al., 2010). Cells were then incubated for 48 h with five serial dilutions of 
the extract, ranging from 12.5 µg/mL to 400 µg/mL (Lima et al., 2014). Following 48 h 
of incubation with the extract (or immediately for the T0 plate), plates were fixed by 
adding ice-cold 10% trichloroacetic acid (w/v, final concentration; Panreac, Barcelona, 
Spain) and stained with 0.4 % SRB (Sigma Aldrich,St. Louis, MO, USA) in 1% (v/v) 
acetic acid. Bound dye was solubilised by adding 10 mM Tris base (Sigma Aldrich, St. 
Louis,MO, USA) and the absorbance was measured at 510 nm in a microplate reader 
(BioTek® Synergy HT, Winooski, VT, USA) (Vaz et al., 2012a). The results were 
expressed as GI50 values (the concentration that inhibited cell growth by 50%) as 
described by Monks et al. (1991). Doxorubicin (tested concentrations from 1.25 x 10-8 
to 2 x 10-7 M) and etoposide (tested concentrations from 9 x 10-7 to 14 x 10-6 M) were 
used as positive controls. The H2O (vehicle used to dissolve the extracts) concentrations 
used (5%) were also tested (control treatments). Another control was included, 
consisting in cells growing in complete culture medium only (blank treatment).  
For the cytotoxicity evaluation, the human breast non-malignant cell line MCF-10A was 
used. The cell line was obtained from ATCC (American Type Culture Collection, 
Manassas, VA). MCF-10A cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM): F12, supplemented with 5% heat inactivated horse serum, 10 µg/ml insulin, 
0.5 µg/ml hydrocortisone, 20 ng/ml epidermal growth factor (EGF), and 100 ng/ml 
cholera toxin (Sigma-Aldrich, St Louis, MO). The cells were routinely cultured in a 
humidified atmosphere with 5% CO2 and at 37ºC and used in experiments when 
reached 70% – 80% confluence. Cells were plated in 96-well plates at the same density 
as MCF-7 (5.0 × 103 cells/well) and allowed to adhere for 24 h. Cells were treated for 
48 h with the different diluted sample solutions and a similar procedure described 
previously for the SRB assay was followed. The results were also expressed as GI50 
values and doxorubicin was used as a positive control.  
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2.4. Cell biological assays used to assess the antitumour activity 
2.4.1. Preparation of cells for subsequent assays 
MCF-7 cells were plated at 1.0 × 105 cells/well in 6-well plates and incubated for 24 h 
to adhere to the plates. Cells were then treated with the phenolic extract of L. vulpinum 
at its GI50 and GI75 concentrations for the following assays: cell proliferation, cell cycle 
analysis, apoptosis and analysis expression of some proteins (i.e., p53, p21, Bcl-2, Bcl-
xL, procaspase 9, PUMA, Bax, PARP, p-H2AX) which are associated with cell cycle 
and apoptosis. Blank cells (treated with medium) or control cells (treated with H2O 
volumes corresponding to the ones used in the treatments with the extract) were also 
included. The percentage of viable cells in relation to Blank cells was also confirmed, 
with the trypan blue exclusion assay. 
For the DNA damage assay, cells were treated with 200 and 250 µg/mL of the phenolic 
extract for 24 h. Blank and control cells were also included and the percentage of viable 
cells was also confirmed. 
 
2.4.2. Cell proliferation analysis 
Cell proliferation was analysed with the BrdU assay, according to the protocol 
previously described by Palmeira et al. (2010). Briefly, cells were treated for 48 h 
(Blank, control or with the different concentrations of the extract). One hour before 
harvesting, cells were incubated with 10 µM BrdU (Sigma Aldrich, St.Louis, MO, 
USA) and were then harvested and fixed in 4% paraformaldehyde (PFA; Panreac, 
Barcelona, Spain) in PBS for 30 min at room temperature. After centrifugation, cell 
pellets were re-suspended in PBS and stored at 4°C. Cell cytospins were prepared and 
incubated in 2 M HCl for 20 min. Following incubation with mouse anti-BrdU antibody 
(diluted 1/10; Dako) for 1 h at room temperature, cells were incubated with anti-mouse-
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Ig-FITC (diluted 1/100; Dako) for 30 min at room temperature. Slides were then 
prepared with Vectashield mounting medium (with DAPI). BrdU incorporation was 
observed in a DM2000 microscope (LEICA; Wetzlar, Germany) and a semi-quantitative 
evaluation was carried out by counting a minimum of 500 cells per slide. 
 
2.4.3. Cell cycle distribution analysis 
Following the 48 h treatments, cells were harvested and fixed with ice-cold 70% ethanol 
and stored at 4°C for at least 12 h, until further analysis. Cells were re-suspended in 
PBS containing RNase A (0.1 mg/mL) and propidium iodide (5 µg/mL). Cellular DNA 
content was analysed by flow cytometry (BD Accuri™ C6 Flow cytometer, USA) and 
the percentage of cells in the G1, S and G2/M phases of the cell cycle (as well as the 
percentage of cells in the sub-G1 peak) was determined using the FlowJo 7.6.5 software 
(Tree Star, Inc., Ashland, OR, USA) after cell debris and aggregates exclusion and 
plotting at least 15 000 events per sample (Vasconcelos et al., 2000). 
 
2.4.4. Apoptosis analysis 
Induced apoptosis was assayed by Flow cytometry using the Human Annexin V-
FITC/PI apoptosis kit (Bender MedSystems, Vienna, Austria), according to the 
manufacturer's instructions, as previously described (Queiroz et al., 2013). Flow 
cytometry was carried out using the flow cytometer mentioned above and plotting at 
least 15 000 events per sample. Data were analysed using the BD Accuri C6 Software 
(version 1.0.264.21).  
 
2.4.5. Protein expression analysis 
For analysis of protein expression, following 48 h of treatments, cell pellets were lysed 
in Winman's buffer (1% NP-40, 0.1 M Tris–HCl pH 8.0, 0.15 M NaCl and 5 mM 
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EDTA) complemented with protease inhibitor cocktail (Roche). The total protein 
content was quantified using the DC™ Protein Assay kit (Biorad, Hercules, CA), 
according to manufacturer's instructions. Proteins (20 µg) were loaded on 12% SDS-
PAGE gel and transferred into a nitrocellulose membrane (Amersham, Pittsburgh, PA, 
USA). The following primary antibodies were used: mouse anti-p53 (1:5000; Santa 
Cruz Biotechnology), mouse anti-p21 (1:250; Calbiochem), mouse anti-PUMA (1:500; 
Santa Cruz Biotechnology), mouse anti-Bax (1:500; Santa Cruz Biotechnology), rabbit 
anti-caspase 9 (1:1000; Cell Signalling Technology), mouse anti-BCl2 (1:100; Dako), 
rabbit BClXL (1:200; Santa Cruz Biotechnology), rabbit anti-PARP (1:2000; Santa Cruz 
Biotechnology), rabbit anti-p-H2A.X (1:200, Santa Cruz Biotechnology) and goat anti-
actin (1:2000, Santa Cruz Biotechnology). The corresponding secondary antibodies 
were: anti-mouse IgG-HRP (1:2000, Santa Cruz Biotechnology), anti-rabbit IgG-HRP 
(1:2000, Santa Cruz Biotechnology) or anti-goat IgG-HRP (1:2000, Santa Cruz 
Biotechnology). The Amersham™ ECL Western Blotting Detection Reagents, the 
Amersham Hyperfilm ECL and the Kodak GBX developer and fixer were used for 
signal detection, as previously described (Lima et al., 2006). 
 
2.4.6. Analysis of DNA Damage 
DNA damage was analysed with the Alkaline Comet Assay 24 h after treatment with 
the phenolic extract or control treatments. This incubation period was selected (instead 
of 48 h) to evaluate the first DNA degradation stages that occurred, prior to cellular 
apoptosis. Hydrogen peroxide was used as positive control (1 mM) and it was added 10 
min before cells harvesting. Harvested cells were stored in 10% DMSO in FBS at -
80ºC, following a procedure previously described by other authors (Seca et al., 2014). 
Briefly, after thawing, cells were washed with PBS, resuspended in 0.6% low melting 
point agarose and quickly poured onto slides, precoated with 1% agarose in water, with 
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the aid of a coverslip. Slides were kept 10 min on ice. After removing the coverslip, 
cells were lysed with ice-cold lysis buffer (100mM Na2EDTA, 2.5M NaCl, 10mM Tris-
HCl, pH 10.0, 1% Triton X-100) for 2 h, in the dark, at 4 ºC, and then washed twice in 
ice-cold distilled water for 10 min. Slides were placed on an electrophoresis tank filled 
with electrophoresis buffer (10 M NaOH; 200mM Na2EDTA) and incubated for 20 min 
to let DNA to unwind. Electrophoresis was carried out for 20 min at 23 V, 300 mA. 
After this period, slides were flooded with neutralisation buffer (0.4 M Tris, pH 7.5) for 
20 min and then rinsed in ice-cold water for 10 min before being allowed to dry at room 
temperature overnight. Slides were rehydrated with distilled water (for 30 min), covered 
with 2.5 µg/mL of propidium iodide solution and incubated for 20 min at room 
temperature in the dark. Propidium iodide was rinsed with distilled water for 30 min and 
slides dried at 37ºC. Comets were visualized using the fluorescent microscope 
mentioned above and representative photographs were taken. The analysis was made 
using the ‘Comet Assay IV v4.3’ imaging system (Perceptive Instruments). A minimum 
of 100 cells per condition were analysed. 
 
2.5. Statistical analysis 
All experimental data is presented as mean ± standard deviation (SD) or standard error 
(SE), from at least three independent experiments (most of them performed in 
duplicate). Statistical analysis was carried out using an unpaired student’s t-test. All 
analyses were performed comparing cells treated with the phenolic extract with Blank 
cells (cells incubated with medium only). *Indicates p < 0.05. 
 
3. Results and discussion 
3.1. Chromatographic characterization of the phenolic extract from L. vulpinum  
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To our knowledge, there are no studies concerning the chemical characterization of L. 
vulpinum extracts. Based on the statement that mushrooms and their components have 
numerous positive health benefits, in the present work it was intend to discover new 
bioactive extracts from unstudied species. For that, we tested a phenolic extract from L. 
vulpinum for its antitumour properties, initiating the study with its chemical 
characterization.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Phenolic acids individual profile of the studied phenolic extract from Leccinum 
vulpinum Watling. 1- gallic acid; 2- protocatechuic acid; 3- p-hydroxybenzoic acid; 4- 
cinnamic acid.  
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Table 1  
Phenolic acids and cinnamic acid present in the phenolic extract from Leccinum 
vulpinum Watling (µg/g extract)	
 
As previously referred, mushroom phenolic compounds have been reported to 
contribute to the bioactivity of several species. The studied phenolic extract exhibited 
the presence of gallic acid (18.4 µg/g extract), protocatechuic acid (77 µg/g extract) and 
p-hydroxybenzoic acid (20 µg/g extract; Fig. 1; Table 1).  
Accordingly, the main molecular group of phenolic compounds found in this mushroom 
specie was the hydroxybenzoic acids one, which comprises, besides p-hydroxybenzoic 
acid, gallic and protocatechuic acids. Gallic acid has been referred as having anticancer 
properties in several models such as prostate carcinoma DU145 and 22Rv1 cells (Kaur 
et al., 2009), non-small-cell lung cancer NCI-H460 cells (Ji et al., 2009), HeLa cervical 
cancer cells (You et al., 2010), leukaemia K562 cells (Reddy et al., 2012), and 
glioblastoma U87 and U251n cells, and having been pointed out as a valuable candidate 
for treatment of brain tumour (Lu et al., 2010). Protocatechuic acid has also been 
referred as having antitumour potential, namely as an inducer of cell death in HepG2 
hepatocellular carcinoma cells (Yip et al., 2006), human breast cancer MCF-7 cells, 
lung cancer A549 cells, cervix HeLa cells, and prostate cancer LNCaP cells (Yin et al., 
2009). Even though there are not many publications regarding the antitumour potential 
of p-hydroxybenzoic acid, it has been reported as a component of some phenolic 
Gallic acid Protocatechuic acid p-Hydroxybenzoic acid Cinnamic acid Total phenolic acids 
 
 
 
 
 
 
 
 
18.4 ± 0.3 77 ± 1 20 ± 1 38.0 ± 0.2 115.0 ± 1 
Values correspond to the mean ± SD. 
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extracts with cytotoxicity/antitumour activity. This is the case of fermentation products 
of the medicinal plant Houttuynia cordata (Senawong et al., 2014) or honey samples 
(Spilioti et al., 2014). In some studies with mushrooms, the synergistic effects 
concerning the cytotoxicity of phenolic acids in human tumour cell lines have been 
reported, even when the isolated compounds (e.g. p-hydroxybenzoic acid) do not have 
such activity on their own (Heleno et al., 2014; Vaz et al., 2012a). Thus, p-
hydroxybenzoic acid may exert antitumour effects when associated with other 
compounds, since there is also evidence that their own derivatives have antiproliferative 
and proapoptotic activities (Seidel et al., 2014). 
Cinnamic acid was also found in the studied mushroom extract (38.0 µg/g extract). 
Cinnamic acid has been also reported as having anticancer properties. This natural 
compound inhibits the proliferation and modulates brush border membrane enzyme 
activities in colorectal adenocarcinoma Caco-2 cell line (Ekmekcioglu et al., 1998).  
Considering these aspects, the presence of the mentioned phenolic compounds (and of 
the related compound cinnamic acid) in L. vulpinum phenolic extract is possibly 
responsible for its bioactive properties. 
 
3.2. Cell growth inhibitory activity of the phenolic extract from L. vulpinum in human 
tumour cell lines and cytotoxicity in MCF-10A cells 
There are some reports on tumour cell growth inhibitory activity of some phenolic 
extracts/compounds from other species of mushrooms (Heleno et al., 2014; Patel and 
Goyal, 2012; Vaz et al., 2012a). Nevertheless, to our knowledge such activity has never 
been previously investigated in the phenolic extracts of the L. vulpinum species. 
Therefore, in this work its effect on tumour cell growth inhibition was evaluated using a 
panel of four human tumour cell lines (MCF-7, NCI-H460, HCT-15 and AGS). 
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Table 2 
Determined GI50 concentrations of the phenolic extract from Leccinum vulpinum 
Watling 
 
GI50 
values 
HCT-15 NCI-H460 AGS MCF-7 MCF-10A 
53 ± 6 µg/mL 116 ± 8 µg/mL 135 ± 2 µg/mL 99 ± 11 µg/mL 297 ± 9 µg/mL 
Positive controls  
Etoposide 
6.8 ± 0.6 µM 
Doxorubicin 
25 ± 2 nM 
Doxorubicin 
23 ± 2 nM 
Doxorubicin 
26 ± 3 nM 
Doxorubicin 
19 ± 3 nM 
Values correspond to the mean ± SE of three independent experiments, carried out with 
duplicates. 
 
 
The extract inhibited the cell growth of all the cell lines tested (Table 2) and the lowest 
GI50 concentrations were obtained in HCT-15 and MCF-7 cell lines. Positive controls 
were used for all the tested cells. Doxorubicin and etoposide are both used in cancer 
chemotherapy (Varaprasad et al., 2010; Chabner and Longo, 2011). Doxorubicin was 
selected as the main positive control; however, since the HCT-15 cell line was not very 
sensitive to this drug, presenting GI50 values higher than the maximum tested (200 nM), 
etoposide was used as a positive control in this case.  
It was decided to continue the studies in the MCF-7 cells since, as aforementioned, 
there is evidence for an inverse relationship between mushroom consumption and breast 
cancer risk. 
In order to assess the safety of using this phenolic extract, its cytotoxicity was tested in 
the human breast non-malignant cell line, MCF-10A. Although the phenolic extract of 
L. vulpinum exhibited some cytotoxicity on these cells, the values of GI50 obtained were 
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much higher than those obtained in the breast tumour (MCF-7) cells (three times higher; 
Table 2). Therefore, the phenolic extract from L. vulpinum inhibited the growth of 
different human tumour cell lines, but was less toxic to the non-tumourigenic breast 
cancer cell line. 
 
3.3. Effects of the phenolic extract of L. vulpinum on the human MCF-7 breast cancer 
cell line 
L. vulpinum phenolic extract decreased proliferation of MCF-7 cells  
There are some reports regarding the effect of mushroom extracts of other mushroom 
species on the proliferation of human tumour cell lines (dos Santos et al., 2013 and 
2014; Yu et al., 2014). In order to verify if the L. vulpinum phenolic extract interfered 
with the proliferation of MCF-7 cells, the levels of BrdU incorporation were analysed 
following 48 h treatment. As shown in Fig. 2, the studied extract reduced cellular 
proliferation. Nevertheless, the effect on cell proliferation was only considered 
statistically significant with the GI75 concentration (159 µg/mL). The fact the GI50 
concentration of the extract did not cause a statistically significant reduction on cell 
proliferation, may be due to an effect on cellular apoptosis at that concentration (see 
section 3.3.3. below) rather than an effect on cell cycle (proliferation). Indeed, it is 
possible that, although there is a decrease in the cell number following treatment with 
the 
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GI50 concentration, the % of cells in the S-phase (which incorporate BrdU) is not 
altered. 
 
 
 
 
 
 
 
 
 
Fig. 2. Cellular proliferation of MCF-7 cells treated with a phenolic extract of Leccinum 
vulpinum Watling analysed by the BrdU incorporation assay. Cells were treated with the 
GI50 and GI75 concentrations of the phenolic extract for 48 h. Appropriate controls were 
included: untreated cells (Blank) and cells treated with the corresponding volumes of 
the extract solvent (H2O; Control 1 and Control 2). Results represent the mean ± SE of 
three independent experiments. *Represents p < 0.05 when comparing the effect of the 
studied phenolic extract with the Blank cells. 
 
L. vulpinum phenolic extract did not alter cell cycle distribution of MCF-7 cells 
Once differences in cellular proliferation were observed, the next step was to determine 
whether the extract caused cell cycle arrest.  As previously referred, MCF-7 cells were 
treated with the GI50 and GI75 concentrations of the phenolic extract under study. From 
the analysis of the results obtained, no significant differences were observed in the 
different phases of the cell cycle (Fig. 3).  
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Fig. 3. Cell cycle analysis of MCF-7 cells treated with a phenolic extract of Leccinum 
vulpinum Watling. Cells were treated with the GI50 and GI75 concentrations of the 
phenolic extract for 48 h. Appropriate controls were included: untreated cells (Blank) 
and cells treated with the corresponding volumes of the extract solvent (H2O; Control 1 
and Control 2). Results represent the mean ± SE of at least three independent 
experiments. *Represents p < 0.05 when comparing the effect of the studied phenolic 
extract with the Blank cells. 
 
Having decreased cellular proliferation, we would expect that the extract would cause 
cell cycle arrest. These discrepancies may also be justified by the fact that cells may be 
dying by apoptosis (see section 3.3.3. bellow). Indeed, even though no significant 
differences in the cell cycle profile were observed, there was a significant increase in 
the sub-G1 peak of the cells that had been treated with the GI75 concentration of the 
extract, which is suggestive of cellular apoptosis. Nevertheless, this sub-G1 peak cannot 
be used as a conclusive marker of apoptosis (Kajstura et al., 2007). In conclusion, these 
results suggest that one of the possible mechanisms of action of this phenolic extract is 
the induction of apoptosis.  
 
L. vulpinum phenolic extract induced apoptosis in MCF-7 cells 
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Due to the above mentioned results (sections 3.3.1 and 3.3.2), the apoptotic levels of 
MCF-7 cells treated with the phenolic extract of L. vulpinum were studied, with the 
Annexin V-FITC/PI flow cytometry assay. The results obtained are presented in Table 
3.  
The studied phenolic extract increased apoptosis in MCF-7 cells that had been treated 
for 48 h. In Blank and control cells the apoptosis levels were approximately 6 to 9%, 
which were within the normal values usually obtained for this cell line (Vaz et al., 
2012b). When cells were treated with the GI50 concentration of the extract the 
percentage of cells undergoing apoptosis increased to 13.4% and when cells were 
treated with the GI75 concentration of the extract the levels of apoptosis increased to 
27%; in both cases, the increase was considered statistically significant (Table 3). 
Although flow cytometry is a very sensitive method, in order to corroborate the results 
obtained, a fluorescence microscopic examination of cells was performed. Cellular 
treatment with the studied phenolic extract caused formation of apoptotic bodies 
(marked with arrows),	which is more visible with the GI75 treatment (Fig. 4). 
 
Table 3 
Percentage of MCF-7 cells undergoing programmed cell death following treatment with 
a phenolic extract of Leccinum vulpinum Watling 
 
Treatment 
Blank Control 1 Control 2 GI50 GI75 
6 ± 1 8.3 ± 0.6 9 ± 1 13.4 ± 0.8* 27 ± 4* 
Values correspond to the mean ± SE of three independent experiments. *Represents p < 0.05 
when comparing the effect of the studied phenolic extract with the Blank cells. 
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Fig. 4. Analysis of the apoptotic bodies in MCF-7 cells treated with a phenolic extract 
of Leccinum vulpinum Watling. Fluorescence microscopy images are representative of 3 
independent experiments. Cell nuclei are stained with DAPI (blue). Arrows indicate 
apoptotic bodies; bar corresponds to 20 µm.   
 
Therefore, it was confirmed that cellular treatment with this extract induced apoptosis. 
In addition, the effect of the mushroom extract on the expression of some proteins 
involved in apoptosis was determined by Western blot (Fig. 5). Results show that 
treatment of MCF-7 cells for 48 h with the GI75 concentration of the extract caused a 
significant increase in the p53 tumour suppressor protein. This protein becomes 
activated in response to stress conditions and induces p21 expression, which acts as a 
regulator of the cell cycle at the G1 checkpoint (Tsujitani et al., 2012). Accordingly, 
p21 levels were also found increased following cellular treatment with the GI75 
concentration of the extract. 
Considering the verified increase in p53 levels and since p53 is a transcriptional factor 
which enhances the expression of genes involved in apoptosis such as Bax and PUMA, 
the cellular levels of Bax and PUMA were also evaluated (Charvet et al., 2011). No 
alterations were observed in Bax and PUMA expression levels with either of the 
treatments (GI50 and GI75; Fig. 5A and 5B). Being regulated by p53, their expression 
levels would be expected to be enhanced; however, the results obtained may be justified 
by the fact that only the 48h time point was analysed or that other mechanisms of 
apoptosis induction are being induced. Therefore, the levels of Bcl-2 and Bcl-xL were 
also evaluated by Western Blot. The cellular levels of both protein levels were reduced 
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following treatment with the extract (Fig. 5A), and in the case of Bcl-xL this reduction 
was found to be statistically significant for both concentrations of the extract (GI50 and 
GI75; Fig. 5B). The verified decrease in the Bcl-2 levels may be a cause or a 
consequence of the verified apoptosis. Indeed, apoptosis results in the activation of 
caspases which cause a series of cascade reactions that cleave essential proteins 
throughout the cell. Bcl-2 and Bcl-xL (anti-apoptotic proteins) may be cleaved by 
caspases, causing a reduction in their cellular levels and therefore further potentiating 
the apoptotic process (Fujita et al., 1998; Kirsch et al., 1999; Liang et al., 2002). So, the 
verified decrease in Bcl-2 and Bcl-xL may be a cause and/or a consequence of the 
verified increase in apoptosis. 
Caspase-9 is the initiator caspase, whose activation is required for subsequent 
downstream caspase activation (Wu, 2014). Treatment of MCF-7 cells with the 
mushroom extract caused a decrease in procaspase-9 levels, suggesting that caspase-9 
was activated.  Usually, this decrease is accompanied by an appearance of a 37 kD 
cleavage product in the Western Blots (Sharma et al., 2012); however, we were not able 
to detect this band with the used antibody.  Additionally, treatment with the GI75 
concentration of the phenolic extract significantly decreased total PARP levels (Fig. 5A 
and 5B), which is also typical of the activation of the mitochondrial pathway of 
apoptosis (Huang et al., 2012).  
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Fig. 5. Expression of apoptosis- and DNA damage-related proteins in MCF-7 cells 
treated with a phenolic extract of Leccinum vulpinum Watling. (A) Western blot images 
representative of at least three independent experiments. Actin was used as a loading 
control. (B) Densitometry analysis of the Western blots. Cells were treated with the GI50 
and GI75 concentrations of the phenolic extract for 48 h. Appropriate controls were 
included: untreated cells (Blank) and cells treated with the corresponding volumes of 
the extract solvent (H2O; Control 1 (CTR1) and Control 2 (CTR2)). Results represent 
the mean ± SE of three independent experiments and are expressed after normalization 
of the values obtained for each protein with the values obtained for actin and further 
expressed in relation to Blank cells. *Represents p < 0.05 when comparing the effect of 
the studied phenolic extract with the Blank cells.   
 
L. vulpinum phenolic extract induced DNA damage  
One of the causes of apoptotic cell death, namely via the intrinsic pathway, is DNA 
damage (Roos and Kaina, 2013). Accordingly, it was decided to analyze the levels of p-
H2A.X, a protein also related to DNA damage and repair. Although the results observed 
in the Fig. 5A (Western blot) seem to indicate an increase in p-H2A.X levels, we found 
that this increase was not statistically significant (Fig. 5B).  
In order to confirm if the mushroom extract induced DNA damage, the comet assay was 
performed. As aforementioned, cells were treated for 24 h with two different and high 
extract concentrations, 200 and 250 µg/mL (both higher than the GI75), in order to see 
the induction of DNA damage before the reduction in the number of viable cells due to 
apoptosis occurred (which would mean that a very small number of cells would be 
analysed).  By measuring the percentage of tail DNA obtained, a significant increase 
upon treatment with 250 µg/mL of the extract was observed (Fig. 6). Therefore, it can 
be concluded that the phenolic extract from L. vulpinum causes effectively DNA 
damage.  
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Fig. 6. Quantification of the % of Tail DNA representative of DNA damage induced in 
MCF-7 cells treated with a phenolic extract from Leccinum vulpinum Watling. Cells 
were treated with 200 µg/mL and 250 µg/mL of the studied phenolic extract for 24 h. 
Appropriate controls were included: untreated cells (Blank), cells treated with the 
positive control (H2O2, 1 mM) and cells treated with the corresponding volumes of the 
extract solvent (Control 1 and Control 2). 
 
 
 
Overall, the phenolic extract from L. vulpinum seems to affect the human MCF-7 breast 
cancer cell line by causing DNA damage, which then probably caused a decrease in 
cellular proliferation and an increase in cell dead by apoptosis.  
Indeed, the results obtained by flow cytometry (as well as fluorescence microscopy) 
were conclusive and reported an increase in the percentage of MCF-7 cells undergoing 
programmed cell death following treatment with the studied phenolic extract. Moreover, 
it is well known that PARP is involved in the repair of DNA damage, being cleaved 
during apoptosis. In fact, cleavage of PARP by caspases is considered to be a hallmark 
of apoptosis (Chaitanya et al., 2010; Yang et al., 2004). Therefore, our findings clearly 
suggest the induction of apoptosis by this extract. The decrease in procaspase-9 levels 
following treatment means that caspase-9 was activated. This protease is known to then 
activate the downstream caspases-3 and/or -7, which in turn cleave PARP (Ferguson et 
al., 2003).  
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Additionally, even though the results obtained for p-H2AX have not been conclusive, 
the Comet assay proved that the extract induced DNA damage of MCF-7 cells. 
 
4. Conclusions 
This work was the first to report the bioactivity of L. vulpinum phenolic extract.  This 
extract is characterised by the presence of hydroxybenzoic acids (gallic, protocatechuic 
and p-hydroxybenzoic acids) and the related compound cinnamic acid.  
This mushroom extract seems to inhibit the growth of the human MCF-7 breast cancer 
cell line, by inducing DNA damage, inhibiting cellular proliferation and leading to cell 
death by apoptosis. This extract also revealed cytotoxic effects in the human breast non-
malignant cell line, but at much higher concentrations.  
This work has provided further knowledge on the potential of L. vulpinum phenolic 
extract as a source of bioactive compounds with antitumour potential. 
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